A First-in-Human Study of HH160 in Patients With Advanced Solid Tumors

Starting soon · Phase 1

Conditions studied: Solid Tumor, Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Renal Cell Carcinoma, Endometrial Cancer, Cervical Cancer, Small-cell Lung Cancer, Triple Negative Breast Cancer, Urothelial Carcinoma, Gastroesophageal Adenocarcinoma

In brief

This study is evaluating the safety, side effects, how the body processes HH160, and its early anticancer activity when given alone or with other cancer treatments in participants with advanced solid tumors. The study will also identify the recommended dose for future studies. The trial includes two phases and is expected to last about 4 years, with treatment and follow-up lasting approximately 6-12 months each.

Key facts

Study ID

NCT07623369

Run by

Huahui Health

People needed

56

Starts

2026-06-01

Expected to finish

2028-08-01

Last updated by the study team

2026-06-03

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.